Pulse Biosciences CS (PLSE) Stock Price, Quote & News

Company Profile

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; CellFX nsPFA Percutaneous Electrode system for soft tissue ablation in surgical setting; CellFX nsPFA Cardiac Clamp designed for use in surgical treatment of atrial fibrillation (AF); CellFX nsPFA 360° Cardiac Catheter designed to provide a circumferential, or circular, ablation in a single treatment cyc...

Industry: Medical Instruments & Supplies

Sector: Healthcare

Phone: 510 906 4600

Website: www.pulsebiosciences.com

Address:

601 Brickell Key Drive, Suite 1080, Miami, United States

TruthBroker2 Jan. 6 at 3:47 PM

$SMMT $PLSE

0 · Reply

AdLucrum Jan. 6 at 12:05 PM

$PLSE https://www.businesswire.com/news/home/20260106087962/en/Pulse-Biosciences-Selected-to-Present-Late-Breaking-Data-from-the-nPulse-Cardiac-Catheter-Study-at-the-AF-Symposium

0 · Reply

AdLucrum Jan. 6 at 10:20 AM

$BEAT $PRPH $PLSE

0 · Reply

BubbaHoTep Jan. 5 at 4:08 PM

$PLSE Strong

1 · Reply

TruthBroker2 Jan. 5 at 10:39 AM

$SMMT $PLSE

0 · Reply

TruthBroker2 Jan. 3 at 1:57 PM

$PLSE

0 · Reply

TruthBroker2 Jan. 1 at 8:35 PM

$SMMT $PLSE Happy New Year

0 · Reply

TruthBroker2 Dec. 31 at 6:27 PM

$SMMT $PLSE

0 · Reply

bob2013 Dec. 31 at 1:25 AM

$PLSE January 14 2026!!!

0 · Reply

TruthBroker2 Dec. 30 at 6:03 PM

$PLSE

0 · Reply

Pulse Biosciences Selected to Present Late-Breaking Data from the nPulse Cardiac Catheter Study at the AF Symposium

Dec 29, 2025, 4:05 PM EST - 8 days ago

Pulse Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 19, 2025, 4:05 PM EST - 18 days ago

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 18, 2025, 7:00 AM EST - 19 days ago

Pulse Biosciences Announces FDA IDE Approval to Initiate its nPulse Cardiac Catheter Ablation System Study for the Treatment of Atrial Fibrillation

Dec 9, 2025, 7:00 AM EST - 4 weeks ago

Pulse Biosciences, Inc. Announces Initiation of Research Collaboration for the Treatment of Benign and Malignant Thyroid Tumors with nPulse™ Technology

Nov 6, 2025, 4:05 PM EST - 2 months ago

Pulse Biosciences, Inc. Announces Participation in Upcoming Investor Conferences

Nov 5, 2025, 11:01 PM EST - 2 months ago

Pulse Biosciences, Inc. (PLSE) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 4:05 PM EST - 2 months ago

Pulse Biosciences Reports Business Updates and Third Quarter 2025 Financial Results

Oct 24, 2025, 7:00 AM EDT - 2 months ago

Pulse Biosciences Announces First Enrollment in the NANOCLAMP AF Study

Oct 22, 2025, 4:05 PM EDT - 2 months ago

Pulse Biosciences Schedules Third Quarter 2025 Business Updates and Financial Results Conference Call for November 5, 2025

Oct 10, 2025, 7:00 AM EDT - 3 months ago

Pulse Biosciences Announces Presentation of Late-Breaking Data From the nPulse™ Cardiac Surgical System First-in-Human Feasibility Study at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting

Oct 7, 2025, 7:00 AM EDT - 3 months ago

Pulse Biosciences Announces Clinical Data Highlighting its nPulse™ Cardiac Surgical System to be Presented at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting

Sep 10, 2025, 7:00 AM EDT - 4 months ago

Pulse Biosciences' nPulse™ Technology to be Featured at the American Thyroid Association 2025 Annual Meeting

Sep 8, 2025, 7:00 AM EDT - 4 months ago

Pulse Biosciences Announces FDA IDE Approval to Initiate its nsPFA Cardiac Surgery System Study for the Treatment of Atrial Fibrillation

Sep 2, 2025, 7:00 AM EDT - 4 months ago

Pulse Biosciences Announces First Successful Procedures in PRECISE Benign Thyroid Nodule (BTN) Study

Aug 26, 2025, 7:00 AM EDT - 4 months ago

Pulse Biosciences Announces Publication of First-In-Human Data for Treatment of Benign Thyroid Nodules in the Journal Thyroid

Aug 12, 2025, 9:06 PM EDT - 5 months ago

Pulse Biosciences, Inc. (PLSE) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 4:05 PM EDT - 5 months ago

Pulse Biosciences Reports Business Updates and Second Quarter 2025 Financial Results

Aug 1, 2025, 7:00 AM EDT - 5 months ago

Pulse Biosciences To Present at the 45th Canaccord Genuity Annual Growth Conference

Jul 29, 2025, 4:05 PM EDT - 5 months ago

Pulse Biosciences Schedules Second Quarter 2025 Business Updates and Financial Results Conference Call for August 12, 2025

May 10, 2025, 11:02 PM EDT - 8 months ago

Pulse Biosciences, Inc. (PLSE) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:05 PM EDT - 8 months ago

Pulse Biosciences Reports Business Updates and First Quarter 2025 Financial Results

May 6, 2025, 4:05 PM EDT - 8 months ago

Pulse Biosciences To Present at the BofA Securities 2025 Health Care Conference

May 1, 2025, 7:00 AM EDT - 8 months ago

Pulse Biosciences' Nanosecond PFA Technology to be Featured at The American Association for Thoracic Surgery 2025 Annual Meeting

Apr 24, 2025, 4:05 PM EDT - 9 months ago

Pulse Biosciences Schedules First Quarter 2025 Financial Results Conference Call for May 8, 2025

Apr 23, 2025, 7:00 AM EDT - 9 months ago

Pulse Biosciences' Nanosecond PFA Technology to be Featured at The Heart Rhythm Society 2025 Annual Meeting

Mar 27, 2025, 7:46 PM EDT - 10 months ago

Pulse Biosciences, Inc. (PLSE) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 4:05 PM EDT - 10 months ago

Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2024 Financial Results

Mar 26, 2025, 4:05 PM EDT - 10 months ago

Pulse Biosciences To Present at the 24th Annual Needham Virtual Health Care Conference

Mar 7, 2025, 8:00 AM EST - 10 months ago

Pulse Biosciences Schedules Fourth Quarter & Full Year 2024 Financial Results Conference Call for March 27, 2025

Feb 20, 2025, 4:05 PM EST - 11 months ago

Pulse Biosciences To Present at the TD Cowen 45th Annual Health Care Conference

Feb 4, 2025, 8:00 AM EST - 1 year ago

Pulse Biosciences, Inc. Appoints Jon Skinner as Chief Financial Officer

Jan 30, 2025, 8:00 AM EST - 1 year ago

Pulse Biosciences' Nanosecond PFA Technology to Be Featured in Presentations at North American Society for Interventional Thyroidology Annual Meeting

Jan 21, 2025, 7:00 AM EST - 1 year ago

Pulse Biosciences Announces Late-Breaking Data from its Nanosecond PFA 360° Cardiac Catheter System First-In-Human Feasibility Study Presented at the AF Symposium

Jan 13, 2025, 7:00 AM EST - 1 year ago

Pulse Biosciences' Nanosecond PFA Technology to be Featured in Multiple Presentations at the AF Symposium

Jan 10, 2025, 8:00 AM EST - 1 year ago

Pulse Biosciences, Inc. Appoints Paul LaViolette as Chief Executive Officer

Jan 3, 2025, 9:00 AM EST - 1 year ago

Pulse Biosciences To Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 23, 2024, 4:30 PM EST - 1 year ago

Pulse Biosciences, Inc. Announces Planned Redemption of Warrants

Dec 19, 2024, 8:00 AM EST - 1 year ago

Pulse Biosciences, Inc. Announces Election to Exercise Company Warrants

Dec 17, 2024, 8:00 AM EST - 1 year ago

Pulse Biosciences Announces Publication in the Journal of Thoracic and Cardiovascular Surgery

Oct 31, 2024, 2:25 PM EDT - 1 year ago

Pulse Biosciences Announces Positive Clinical Data Presented at the American Thyroid Association

Oct 30, 2024, 9:42 PM EDT - 1 year ago

Pulse Biosciences, Inc. (PLSE) Q3 2024 Earnings Call Transcript

Oct 30, 2024, 4:05 PM EDT - 1 year ago

Pulse Biosciences Reports Business Updates and Third Quarter 2024 Financial Results

Oct 30, 2024, 4:02 PM EDT - 1 year ago

Pulse Biosciences Announces Appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology

Oct 21, 2024, 8:00 AM EDT - 1 year ago

Pulse Biosciences Schedules Third Quarter 2024 Financial Results Conference Call for October 30, 2024

Aug 12, 2024, 6:50 PM EDT - 1 year ago

Pulse Biosciences Inc. (PLSE) Q2 2024 Earnings Call Transcript

Aug 12, 2024, 4:05 PM EDT - 1 year ago

Pulse Biosciences Reports Business Updates and Preliminary Second Quarter 2024 Financial Results

Aug 12, 2024, 4:01 PM EDT - 1 year ago

Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors

Aug 8, 2024, 8:00 AM EDT - 1 year ago

Pulse Biosciences, Inc. Announces Successful Treatment of Patients in First-in-Human Study with its Nano-PFA Cardiac Surgery System

TruthBroker2 Jan. 6 at 3:47 PM

$SMMT $PLSE

0 · Reply

AdLucrum Jan. 6 at 12:05 PM

$PLSE https://www.businesswire.com/news/home/20260106087962/en/Pulse-Biosciences-Selected-to-Present-Late-Breaking-Data-from-the-nPulse-Cardiac-Catheter-Study-at-the-AF-Symposium

0 · Reply

AdLucrum Jan. 6 at 10:20 AM

$BEAT $PRPH $PLSE

0 · Reply

BubbaHoTep Jan. 5 at 4:08 PM

$PLSE Strong

1 · Reply

TruthBroker2 Jan. 5 at 10:39 AM

$SMMT $PLSE

0 · Reply

TruthBroker2 Jan. 3 at 1:57 PM

$PLSE

0 · Reply

TruthBroker2 Jan. 1 at 8:35 PM

$SMMT $PLSE Happy New Year

0 · Reply

TruthBroker2 Dec. 31 at 6:27 PM

$SMMT $PLSE

0 · Reply

bob2013 Dec. 31 at 1:25 AM

$PLSE January 14 2026!!!

0 · Reply

TruthBroker2 Dec. 30 at 6:03 PM

$PLSE

0 · Reply

Easteregg Dec. 30 at 4:03 PM

$PLSE Lets face it. This company is a turd, the price action suggests it.

1 · Reply

BubbaHoTep Dec. 24 at 10:54 PM

$PLSE $SMMT Wishing you all a Merry Christmas 🎄

1 · Reply

TruthBroker2 Dec. 24 at 12:16 AM

$SMMT $PLSE

0 · Reply

SpectralDelta Dec. 23 at 7:58 PM

$PLSE low attention small cap, if it breaks the tight range with volume the asymmetry is clean

0 · Reply

AdLucrum Dec. 23 at 12:04 PM

$PLSE

0 · Reply

TruthBroker2 Dec. 22 at 2:54 PM

$SMMT $PLSE

0 · Reply

TruthBroker2 Dec. 19 at 6:37 PM

$PLSE

0 · Reply

LeisureSuitLarry Dec. 19 at 4:52 PM

$PLSE

0 · Reply

BubbaHoTep Dec. 19 at 4:42 PM

$PLSE Added yesterday and today.

0 · Reply

AdLucrum Dec. 19 at 4:42 PM

$PLSE

0 · Reply

ZacksResearch Dec. 19 at 4:07 PM

$PLSE just cleared a major regulatory hurdle — this is a big step forward. 🚀 PLSE secured FDA IDE approval to launch its nPulse AF ablation study, moving the program into a critical clinical phase. See what this approval unlocks and why it matters 👉 https://www.zacks.com/stock/news/2806849/plse-wins-fda-ide-approval-to-launch-npulse-af-ablation-study-trial?cid=sm-stocktwits-2-2806849-teaser-25638&ADID=SYND_STOCKTWITS_TWEET_2_2806849_TEASER_25638

0 · Reply

ZacksResearch Dec. 19 at 3:07 PM

$PLSE gets FDA IDE approval for its nPulse Cardiac Catheter Ablation System study! This milestone allows PLSE to kick off a multicenter trial in the U.S., building on promising European data and setting the stage for broader adoption and commercialization in the atrial fibrillation market. PLSE shares have lost 4.5% YTD, contrasting with industry growth. Discover the potential impact for PLSE here 👉 https://www.zacks.com/stock/news/2806849/plse-wins-fda-ide-approval-to-launch-npulse-af-ablation-study-trial?cid=sm-stocktwits-2-2806849-body-25619&ADID=SYND_STOCKTWITS_TWEET_2_2806849_BODY_25619

0 · Reply

Market Cap	907.41M
Revenue (ttm)	0.00
Net Income (ttm)	-53.59M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	176,800
Avg Vol	177,262
Day's Range	N/A - N/A
Shares Out	67.77M
Stochastic %K	75%
Beta	1.69
Analysts	Sell
Price Target	$22.00